Lourd Capital LLC Acquires Shares of 14,218 Merck & Co., Inc. (MRK)

Lourd Capital LLC acquired a new stake in Merck & Co., Inc. (NYSE:MRK) in the 2nd quarter, according to the company in its most recent filing with the SEC. The fund acquired 14,218 shares of the company’s stock, valued at approximately $863,000.

A number of other institutional investors and hedge funds have also modified their holdings of the business. Mckinley Capital Management LLC Delaware raised its position in shares of Merck & Co., Inc. by 5.6% during the second quarter. Mckinley Capital Management LLC Delaware now owns 15,447 shares of the company’s stock worth $938,000 after acquiring an additional 815 shares during the last quarter. Summit X LLC raised its position in shares of Merck & Co., Inc. by 9.2% during the first quarter. Summit X LLC now owns 10,093 shares of the company’s stock worth $552,000 after acquiring an additional 850 shares during the last quarter. Covenant Asset Management LLC raised its position in shares of Merck & Co., Inc. by 1.4% during the second quarter. Covenant Asset Management LLC now owns 62,353 shares of the company’s stock worth $3,785,000 after acquiring an additional 850 shares during the last quarter. Pegasus Asset Management Inc. raised its position in shares of Merck & Co., Inc. by 4.2% during the first quarter. Pegasus Asset Management Inc. now owns 21,794 shares of the company’s stock worth $1,187,000 after acquiring an additional 873 shares during the last quarter. Finally, Alpha Cubed Investments LLC raised its position in shares of Merck & Co., Inc. by 11.0% during the first quarter. Alpha Cubed Investments LLC now owns 8,970 shares of the company’s stock worth $489,000 after acquiring an additional 887 shares during the last quarter. Hedge funds and other institutional investors own 73.08% of the company’s stock.

In other Merck & Co., Inc. news, Chairman Kenneth C. Frazier sold 228,091 shares of the business’s stock in a transaction dated Tuesday, July 31st. The stock was sold at an average price of $65.00, for a total value of $14,825,915.00. Following the completion of the transaction, the chairman now directly owns 938,788 shares of the company’s stock, valued at $61,021,220. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Sanat Chattopadhyay sold 29,208 shares of the business’s stock in a transaction dated Friday, August 3rd. The shares were sold at an average price of $65.20, for a total value of $1,904,361.60. Following the completion of the transaction, the insider now directly owns 70,675 shares of the company’s stock, valued at $4,608,010. The disclosure for this sale can be found here. Insiders sold 406,365 shares of company stock valued at $25,829,990 in the last quarter. 0.32% of the stock is currently owned by corporate insiders.

Merck & Co., Inc. opened at $66.07 on Friday, according to Marketbeat Ratings. The stock has a market capitalization of $179.81 billion, a P/E ratio of 16.60, a P/E/G ratio of 2.30 and a beta of 0.80. The company has a quick ratio of 1.10, a current ratio of 1.33 and a debt-to-equity ratio of 0.61. Merck & Co., Inc. has a 12 month low of $52.83 and a 12 month high of $66.99.

Merck & Co., Inc. (NYSE:MRK) last released its quarterly earnings data on Friday, July 27th. The company reported $1.06 EPS for the quarter, beating analysts’ consensus estimates of $1.03 by $0.03. The business had revenue of $10.47 billion during the quarter, compared to the consensus estimate of $10.28 billion. Merck & Co., Inc. had a return on equity of 32.68% and a net margin of 3.67%. The firm’s revenue was up 5.4% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.01 earnings per share. equities research analysts predict that Merck & Co., Inc. will post 4.27 EPS for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 5th. Investors of record on Monday, September 17th will be issued a $0.48 dividend. The ex-dividend date of this dividend is Friday, September 14th. This represents a $1.92 dividend on an annualized basis and a yield of 2.91%. Merck & Co., Inc.’s dividend payout ratio is presently 48.24%.

A number of equities research analysts have recently weighed in on MRK shares. BMO Capital Markets restated a “buy” rating on shares of Merck & Co., Inc. in a research report on Wednesday, April 25th. Goldman Sachs Group upgraded Merck & Co., Inc. from a “neutral” rating to a “buy” rating and dropped their target price for the stock from $60.15 to $58.83 in a research report on Monday, April 23rd. Zacks Investment Research upgraded Merck & Co., Inc. from a “hold” rating to a “buy” rating and set a $66.00 target price for the company in a research report on Tuesday, April 17th. Deutsche Bank restated a “hold” rating on shares of Merck & Co., Inc. in a research report on Wednesday, April 25th. Finally, Morgan Stanley upgraded Merck & Co., Inc. from an “equal weight” rating to an “overweight” rating and boosted their target price for the stock from $59.80 to $63.00 in a research report on Tuesday, April 17th. Six investment analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $66.24.

About Merck & Co., Inc.

Merck & Co, Inc provides healthcare solutions worldwide. It operates in four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular diseases, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, and fertility diseases.

Read More: Outstanding Shares

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply